Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

This study is testing a three-drug combination — selinexor, venetoclax, and dexamethasone — in people with relapsed or treatment-resistant multiple myeloma that has a specific chromosomal change called t(11;14), which makes venetoclax potentially more effective. **You may be eligible if...** - You are 18 or older with confirmed multiple myeloma - Your myeloma cells have the t(11;14) chromosomal translocation (confirmed by a certified lab test) - You have received at least 2 prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody - Your disease has relapsed or is refractory (not responding) to these prior treatments **You may NOT be eligible if...** - Your myeloma does NOT have the t(11;14) translocation - You have not received the required prior lines of therapy - You have severe organ dysfunction or other health conditions that make these drugs unsafe - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.